These findings shed light on the basis for cardiac pacemaker dysfunction in CAID Syndrome and suggest that improving HCN4 cell surface expression via SGO1 could be a therapeutic approach for pacemaking disorders. The gene discussed is HCN4; the disease is chronic atrial and intestinal dysrhythmia.